Kiran Patel, MD of Janssen @JanssenUS discusses phase 1 results for bispecific antibody amivantamab in thetreatment of patients with advanced non-small cell lung cancer harboring exon 20 insertion mutations.
Read here: https://meetinglibrary.asco.org/record/184802/abstract
Advertisement